Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and | Rousseau et al. EJNMMI Research 2011 1 20 http content 1 1 20 9 EJNMMI Research a SpringerOpen Journal ORIGINAL RESEARCH Open Access Syndecan-1 antigen a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors Caroline Rousseau1 2t Anne Lise Ruellan2t Karine Bernardeau 2 Frangoise Kraeber-Bodéré1 2 3 Sebastien Gouard2 Delphine Loussouarn4 Catherine Sai-Maurel2 Alain Faivre-Chauvet2 John Wijdenes5 Jacques Barbet2 Joelle Gaschet2 Michel Chérel1 2 and Frangois Davodeau2 Abstract Background Overexpression of syndecan-1 CD138 in breast carcinoma correlates with a poor prognosis and an aggressive phenotype. The objective of this study was to evaluate the potential of targeting CD138 by immunoPET imaging and radioimmunotherapy RIT using the antihuman syndecan-1 B-B4 mAb radiolabeled with either 124I or 131I in nude mice engrafted with the triple-negative MDA-MB-468 breast cancer cell line. Method The immunoreactivity of 125I-B-B4 80 was determined and the affinity of 125I-B-B4 and the expression of CD138 on MDA-MB-468 was measured in vitro by Scatchard analysis. CD138 expression on established tumors was confirmed by immunohistochemistry. A biodistribution study was performed in mice with subcutaneous MDA-MB-468 and 125I-B-B4 at 4 24 48 72 and 96 h after injection and compared with an isotype-matched control. Tumor uptake of B-B4 was evaluated in vivo by immuno-PET imaging using the 124I-B-B4 mAb. The maximum tolerated dose MTD was determined from mice treated with 131I-B-B4 and the RIT efficacy evaluated. Results 125I-B-B4 affinity was in the nanomolar range Kd nM . CD138 expression on MDA-MB-468 cells was quite low Bmax X 104 X 102 epitopes cell but all expressed CD138 in vivo as determined by immunohistochemistry. The tumor uptake of 125I-B-B4 peaked at 14 injected dose ID per gram at 24 h and was higher than that of the isotype-matched control mAb
